This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

marstacimab for treating severe haemophilia B

Authoring team

NICE have stated that:

  • marstacimab is recommended, within its marketing authorisation, as an option for preventing bleeding episodes caused by severe (factor IX [9] activity less than 1%) haemophilia B (congenital factor 9 deficiency) in people 12 years and over who:
    • weigh at least 35 kg and
    • do not have factor 9 inhibitors (anti-factor antibodies)

Marstacimab

Tissue factor pathway inhibitor (TFPI) antagonises early coagulation stages by inhibiting tissue factor‐activated FVII (FVIIa) and activated FX (FXa)

  • TFPI is expressed in three isoforms, all sharing the Kunitz‐type inhibitor domain K2, which binds and inhibits activated FXa
  • marstacimab is a human immunoglobulin G1 monoclonal antibody that targets the K2 domain of TFPI
    • intended to reduce the inhibition of FXa by TFPI, thereby augmenting haemostasis through the extrinsic pathway (2)
    • evidence showed that once‐weekly SC marstacimab prophylaxis was well tolerated, with an acceptable safety profile, and maintained long‐term efficacy up to 365 days (2)

The NICE committee noted:

  • treatment for preventing bleeding episodes (prophylaxis) is usually factor 8 replacement therapy or emicizumab in severe haemophilia A, and factor 9 replacement therapy in severe haemophilia B
  • in severe haemophilia A and B, evidence from a clinical trial shows marstacimab reduces the number of bleeding episodes a person has compared with factor 8 or 9 prophylaxis
  • in severe haemophilia A, there is no trial directly comparing marstacimab with emicizumab
    • an indirect comparison suggests marstacimab reduces bleeding episodes by a similar number as emicizumab - but the evidence for this is uncertain
  • in severe haemophilia B, the cost-effectiveness evidence for marstacimab showed it is a cost-effective option compared with factor 9

Reference:

  1. NICE (June 2025). Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies
  2. Mahlangu J et al. Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results. Br J Haematol. 2023 Jan;200(2):240-248.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.